Evidence map›Paper›PMID 34938174›Full record

ArticleFrontiers in pharmacology2021

Effect of

Stephania Contreras-Castillo, Anita Plaza, Jana Stojanova, Gustavo Navarro, Rodolfo Carmona, Fernando Corvalán, Leslie Cerpa, Christopher Sandoval, Daniel Muñoz, Marina Leiva and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 2 countries.

Stephania Contreras-CastilloLaboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Anita PlazaLaboratory of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
Jana StojanovaInterdisciplinary Centre for Health Studies (CIESAL), Universidad de Valparaíso, Valparaíso, Chile.
Gustavo NavarroLaboratory of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
Rodolfo CarmonaLaboratory of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
Fernando CorvalánLaboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Leslie CerpaLaboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Christopher SandovalLaboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Daniel MuñozPharmacy Institute, Faculty of Sciences, Universidad Austral de Chile, Valdivia, Chile.
Marina LeivaLaboratory of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
Luis E CastañedaProgram of Human Genetics, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Nayaret FariasTransplantation Unit, San Juan de Dios Hospital, Santiago, Chile.
Carolina AlvarezTransplantation Unit, San Juan de Dios Hospital, Santiago, Chile.
Gabriel LlullTransplantation Unit, San Juan de Dios Hospital, Santiago, Chile.
Sergio MezzanoLaboratory of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
Leopoldo ArdilesLaboratory of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
Nelson VarelaLaboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
María S RodríguezTransplantation Unit, San Juan de Dios Hospital, Santiago, Chile.
Claudio FloresLaboratory of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
Juan Pablo CayúnLaboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
Paola KrallLaboratory of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
Luis A QuiñonesLaboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
University of Chile · CLAustral University of Chile · CLHospital San Juan de Dios · CLUniversity of Valparaíso · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclosporine (CsA) and tacrolimus (TAC) are immunosuppressant drugs characterized by a narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms in genes related to the metabolism and transport of these drugs, namely

Indexed as

cyclosporinekidney transplantpharmacogeneticspolymorphismstacrolimus

Identifiers

PMID34938174
PMCPMC8685429
OpenAlexW4200305305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.